# US 11,999,745 B2 · Pharmaceutical compounds > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 11,999,745 B2 - Document ID: US11999745B2 - Status: Granted - Kind: B2 - Application number: 17/874,564 - Filed: 2022-07-27 - Published: 2022-12-01 - Granted: 2024-06-04 - Earliest claimed: 2020-12-18 - Assignees: Heptares Therapeutics Limited; Allergan Pharmaceuticals Therapeutics International Limited - Applicants: Heptares Therapeutics Limited - Inventors: Charlotte Fieldhouse; Miles Stuart Congreve - Web page: https://patentgrep.com/patent/US11999745B2 ## CPC - C07D 451/02: containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof - C07D 487/10: Spiro-condensed systems - A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia - A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia - A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] - C07D 271/07: with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical - C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract This invention relates to compounds that are agonists of the muscarinic M1 and M4 receptor and which are useful in the treatment of diseases mediated by the muscarinic M1 and/or M4 receptors. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula (1): and salts thereof. ## Claims ### Claim 1 A compound of formula (1): or a salt thereof. ### Claim 2 (depends on 1) The compound according to claim 1, which is a compound of formula (2): or a salt thereof. ### Claim 3 (depends on 1) A salt of the compound according to claim 1. ### Claim 4 (depends on 1) A pharmaceutically acceptable salt of the compound according to claim 1. ### Claim 5 (depends on 1) An acid addition salt of the compound according to claim 1. ### Claim 6 (depends on 1) A hydrochloride salt of the compound according to claim 1. ### Claim 7 (depends on 1) A monohydrochloride salt of the compound according to claim 1. ### Claim 8 (depends on 1) The compound according to claim 1, which is a compound of formula (2b): ### Claim 9 (depends on 1) The compound according to claim 1, which is a compound of formula (2c): ### Claim 10 (depends on 1) A pharmaceutical composition comprising the compound according to claim 1, or a salt thereof, and a pharmaceutically acceptable excipient. ### Claim 11 (depends on 1) A method of treating a disorder selected from a cognitive disorder and a psychotic disorder in a subject, comprising administering to the subject the compound of claim 1, or a salt thereof. ### Claim 12 (depends on 11) The method according to claim 11, wherein the disorder is Alzheimer's disease. ### Claim 13 (depends on 11) The method according to claim 11, wherein the disorder is dementia with Lewy bodies. ### Claim 14 (depends on 11) The method according to claim 11, wherein the disorder is schizophrenia. ### Claim 15 (depends on 2) A salt of the compound according to claim 2. ### Claim 16 (depends on 2) A pharmaceutically acceptable salt of the compound according to claim 2. ### Claim 17 (depends on 2) An acid addition salt of the compound according to claim 2. ### Claim 18 (depends on 2) A hydrochloride salt of the compound according to claim 2. ### Claim 19 (depends on 2) A monohydrochloride salt of the compound according to claim 2. ### Claim 20 (depends on 1) A method of treating or lessening the severity of acute pain, chronic pain, neuropathic pain, or inflammatory pain in a subject, comprising administering to the subject the compound of claim 1, or a salt thereof. ### Claim 21 (depends on 2) A pharmaceutical composition comprising the compound according to claim 2, or a salt thereof, and a pharmaceutically acceptable excipient. ### Claim 22 (depends on 11) The method according to claim 11, which is a method of treating a cognitive disorder. ### Claim 23 (depends on 22) The method according to claim 22, wherein the cognitive disorder is a cognitive disorder associated with Alzheimer's disease. ### Claim 24 A compound of formula (2): ### Claim 25 (depends on 24) A pharmaceutical composition comprising the compound according to claim 24, and a pharmaceutically acceptable excipient. ### Claim 26 (depends on 24) A method of treating a disorder selected from a cognitive disorder and a psychotic disorder in a subject, comprising administering to the subject the compound according to claim 24. ### Claim 27 (depends on 26) The method according to claim 26, wherein the disorder is a cognitive disorder. ### Claim 28 (depends on 27) The method according to claim 27, wherein the cognitive disorder is a cognitive disorder associated with Alzheimer's disease. ### Claim 29 (depends on 26) The method according to claim 26, wherein the disorder is Alzheimer's disease. ### Claim 30 (depends on 26) The method according to claim 26, wherein the disorder is dementia with Lewy bodies. ### Claim 31 (depends on 26) The method according to claim 26, wherein the disorder is schizophrenia.